Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]


The paper titled “Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients,” contains an inaccurate description of the intraoperative use of medications.

In the Results section it is reported that 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface. We have determined that ambiguity in the design of the electronic case report form resulted in all day-of-surgery drops provided to patients in the LASER suite being reported in the flap interface field. The authors have since clarified with each surgeon who reported intraoperative drug use that the drops were delivered either prior to the flap creation, or following replacement of the flap.

The sentence at the top of page 152 stating: “Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had drops applied directly to the flap interface” should say: “Of note, 31.8% (170/534) of besifloxacin cases and 97.0% (259/267) of moxifloxacin cases had intraoperative drops applied.”

---

**Clinical Ophthalmology** 2013:7 725

© 2013 Nielsen et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.